硝酸甘油作为非小细胞肺癌放疗增敏剂的前瞻性Ⅱ期影像试验
这项单臂Ⅱ期试验(NCT01210378)在42例IB-IV期NSCLC根治性放化疗患者中评估硝酸甘油贴片能否通过改善肿瘤灌注降低乏氧并提高2年总生存。试验因无效分析提前终止,2年OS为58%(95%CI 44-78%),硝酸甘油未能降低肿瘤乏氧,也未改善OS;基线乏氧肿瘤OS更差(p=0.029)。
要点
- 硝酸甘油未能降低NSCLC肿瘤乏氧,也未改善总生存。
- 基线乏氧肿瘤患者OS更差(p=0.029)。
- 硝酸甘油相关毒性主要为头痛(17%)和低血压(2.4%)。
核心结论
- 硝酸甘油未能改善接受根治性放化疗的NSCLC患者的总生存。
- 未显示硝酸甘油具有降低肿瘤乏氧的一般能力。
研究设计与样本
- NCT01210378为单臂Ⅱ期试验,主要终点为2年总生存改善15%。
- 入组IB-IV期NSCLC患者,放疗期间使用Transiderm-Nitro 5贴片。
- 患者在硝酸甘油前后接受DCE-CT和HX4乏氧PET/CT检查。
- 试验在42例患者后经无效分析提前终止。
主要发现
- 中位随访41个月时,2年OS为58%(95%CI 44-78%),中位OS为38个月(95%CI 22-54个月)。
- 硝酸甘油未能降低肿瘤乏氧。
- DCE-CT参数与OS无相关性,而乏氧肿瘤OS更差(p=0.029)。
- HX4高摄取分数变化与肿瘤血流量变化呈负相关(r=-0.650,p=0.022)。
- 硝酸甘油相关毒性限于头痛(17%)和低血压(2.4%)。
临床怎么用
- 不支持在NSCLC根治性放化疗中常规使用硝酸甘油作为放疗增敏剂。
- 基线乏氧影像可能有助于识别预后较差的患者。
局限性
- 试验为单臂设计且样本量小(42例)。
- 治疗方式和患者特征的异质性使生存亚组分析无法进行。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nitroglycerin is proposed as an agent to reduce tumour hypoxia by improving tumour perfusion. We investigated the potential of nitroglycerin as a radio-sensitizer in non-small cell lung cancer (NSCLC) and the potential of functional imaging for patient selection. MATERIAL AND METHODS: Trial NCT01210378 is a single arm phase II trial, designed to detect 15% improvement in 2-year overall survival (primary endpoint) in stage IB-IV NSCLC patients treated with radical (chemo-) radiotherapy and a Transiderm-Nitro 5 patch during radiotherapy. Patients underwent dynamic contrast-enhanced CTs (DCE-CT) and HX4 (hypoxia) PET/CTs before and after nitroglycerin. Secondary endpoints were progression-free survival, toxicity and the prognostic value of tumour perfusion/hypoxia at baseline and after nitroglycerin. RESULTS: The trial stopped after a futility analysis after 42 patients. At median follow-up of 41 months, two-year and median OS were 58% (95% CI: 44-78%) and 38 months (95% CI: 22-54 months), respectively. Nitroglycerin could not reduce tumour hypoxia. DCE-CT parameters did not correlate with OS, whereas hypoxic tumours had a worse OS (p = 0.029). Changes in high-uptake fraction of HX4 and tumour blood flow were negatively correlated (r = -0.650, p = 0.022). The heterogeneity in treatment modalities and patient characteristics combined with a small sample size made further subgroup analysis of survival results impossible. Toxicity related to nitroglyerin was limited to headache (17%) and hypotension (2.4%). CONCLUSION: Nitroglycerin did not improve OS of NSCLC patients treated with (chemo-)radiotherapy. A general ability of nitroglycerin to reduce hypoxia was not shown.
引用
- Reymen BJT, van Gisbergen MW, Even AJG, et al. Nitroglycerin as a radiosensitizer in non-small cell lung cancer: Results of a prospective imaging-based phase II trial. Clin Transl Radiat Oncol. 2019. PMID: 32021913. doi:10.1016/j.ctro.2019.12.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。